Annogen Announces Research Project with Pfizer to TestNon-coding Genetic Sequences
Annogen has begun a research project with Pfizer to functionally test tens of thousands of disease-related non-coding sequence variants for their effect on gene regulation.
Annogen introduces AIM™ service
A new service to identify gene insertions and assess their expression levels for >100,000 integrations in parallel.
Annogen BV, a precision medicine company for the non-coding genome, signs research agreement with top tier pharma company.
Annogen will use its proprietary SuRE™ technology to generate genome-wide regulatory profiles to identify disease-relevant regulatory activity and non-coding sequence variants.
Collaboration agreement with a Tier 1 agricultural firm to research non-coding regulatory DNA.
Annogen started a collaboration with a Tier 1 agri firm to test non-coding DNA fragments predicted to influence the expression of important crop traits.
Annogen signs collaboration agreement with Tier 1 agricultural firm to research non-coding DNA influencing gene expression using SuRE™ screening technology
Annogen started a collaboration with a Tier 1 agricultural firm to identify non-coding DNA fragments in plants’ genomes that influence the expression of important crop traits.
Annogen and KeyGene to collaborate in research on non-coding DNA influencing gene expression
Annogen and KeyGene are to collaborate in identifying non-coding DNA fragments in plants’ genomes that influence the expression of important crop traits.
Annogen incorporated to commercialize SuRE technology for Functional Genome Annotation.
Annogen BV was incorporated with exclusive rights to commercialize the SuRE technology outside the gene therapy field, for drug discovery, pharmacogenomics, cell therapy and agricultural biotechnology.
